NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) and Yungjin Pharm Corporation Ltd (South Korea Stock Market, KRX 003520) today announced that the clinical phase I study of KL1333 has started in Korea and that the first healthy volunteer
KL1333 is a drug intended for treatment of orphan genetic mitochondrial disorders and the in-licensed project is about to enter Phase I clinical development.
NeuroVive Pharmaceutical AB and Yungjin Pharm Corporation Ltd jointly announced that they have entered into a global licensing agreement on Yungjin Pharm's compound KL1333 for genetic mitochondrial disorders.